Ovid Therapeutics (OVID) Leases (2022 - 2025)
Ovid Therapeutics (OVID) has disclosed Leases for 4 consecutive years, with $11.9 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Leases fell 8.9% year-over-year to $11.9 million, compared with a TTM value of $11.9 million through Sep 2025, down 8.9%, and an annual FY2024 reading of $12.8 million, down 7.9% over the prior year.
- Leases was $11.9 million for Q3 2025 at Ovid Therapeutics, down from $12.2 million in the prior quarter.
- Across five years, Leases topped out at $15.7 million in Q1 2022 and bottomed at $11.9 million in Q3 2025.
- Average Leases over 4 years is $13.9 million, with a median of $13.9 million recorded in 2023.
- The sharpest move saw Leases decreased 6.51% in 2023, then fell 8.9% in 2025.
- Year by year, Leases stood at $14.9 million in 2022, then decreased by 6.89% to $13.9 million in 2023, then dropped by 7.9% to $12.8 million in 2024, then decreased by 6.88% to $11.9 million in 2025.
- Business Quant data shows Leases for OVID at $11.9 million in Q3 2025, $12.2 million in Q2 2025, and $12.5 million in Q1 2025.